Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
不适用
已完成
NCT05323994
| 适应症 | Depression, COVID-19 |
|---|
| 分期 | 不适用 |
|---|
| 申办方 | Servier Russia |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 104 人 |
|---|
| 开始日期 | 2022年4月19日 |
|---|
| 完成日期 | 2023年2月20日 |
|---|
| 结果公布日 | 2024年10月17日 |
|---|
摘要
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks of treatment. 10 clinics and 10 of psychiatrists and neurologists across the country will participate in the study and it is estimated that each investigating physician will enroll 10 patients.
Antidepressive Effectiveness of Agomelatine in Patients With Depression Episode Occurred After COVID-19 Assessed by HAMD-17 After 8 Weeks of Treatment in the Daily Clinical Practice.
8 weeks · score on a scale
| Patients With Depression Occurred After COVID 19 | 10.9 ± 4.90 score on a scale |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。